LA JOLLA, Calif.--(BUSINESS WIRE)--Traversa Therapeutics, a preclinical-stage biopharmaceutical company developing novel RNA interference (RNAi) technologies, announced today the successful completion of its Series B financing, raising $5 million. The financing was led by Morningside Venture Investments Ltd., and joined by Mesa Verde Venture Partners and existing investors.
